tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'CRO'

Nuvilex, Inc. Applying for Orphan Drug Status to Market Pancreatic Cancer Treatment without Competition

Nuvilex, Inc. Applying for Orphan Drug Status to Market Pancreatic Cancer Treatment without Competition

Written by ι Stock Market Media Group — April 22, 2014

When Nuvilex, Inc. (OTCQB: NVLX) named Clinical Network Services (CNS) as the Contract Research Organization (CRO) for its late phase clinical trials in advanced pancreatic cancer, the company also stated it will apply for “Orphan Drug” status.  This is a designation that will allow Nuvilex to exclusively market its pancreatic cancer treatment using the Cell-in-a-Box® technology combined with the anticancer drug ifosfamide.

Treatments for pancreatic cancer engender an Orphan Drug designation in most ...

Read More →
0

Nuvilex, Inc. Could Obtain FDA Accelerated Approval After Phase 2b Clinical Trial

Nuvilex, Inc. Could Obtain FDA Accelerated Approval After Phase 2b Clinical Trial

Written by ι Stock Market Media Group Staff — April 17, 2014

Nuvilex, Inc. (OTCQB: NVLX) has once again delivered a major announcement as it advances its pancreatic cancer treatment toward late phase clinical trials. Nuvilex continues to put forth what is turning into a well thought out game plan for the future of treating advanced pancreatic cancer. It’s a game plan that could include obtaining accelerated FDA approval of its pancreatic cancer treatment if it can produce the same strong results in an announced ...

Read More →
0

Nuvilex, Inc. Lands Dr. Daniel Von Hoff to Lead Clinical Trials and TD2 as Contract Research Organization (CRO)

Written by ι Stock Market Media Group Staff — April 1, 2014

World Renowned Dr. Daniel Von Hoff to Lead Nuvilex’s Clinical Trials

Nuvilex Signs TD2 as Contract Research Organization (CRO)

  • Oncology Pioneer Dr. Daniel Von Hoff Agrees to Lead Nuvilex’s Pancreatic Cancer Clinical Trials
  • Dr. Von Hoff Developed Eli Lilly’s Gemzar®
  • Dr. Von Hoff Developed  Celgene’s Abraxane® 
  • Dr. Von Hoff is the World’s Leading Authority on Pancreatic Cancer & Now He will Lead Nuvilex’s Clinical Trials
  • Nuvilex Also Retains TD2 – The Precision Oncology CRO™ for Clinical Trials

The News Released This Morning by NVLX is Industry Changing and it will surely reverberate ...

Read More →
0
ContactUs.com